1st fully AI designed drug for lung disease enters human clinical trials – ET HealthWorld
Hong Kong, In a first, a drug discovered and designed using artificial intelligence (AI) for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic disease that causes scarring in the lungs, has entered human clinical trials. Hong Kong-based biotechnology company Insilico Medicine, in a statement, announced that the Phase II trial on oral dosage of … Read more